Merck & Co Inc (MRK)

MRK on New York Consolidated

60.89USD
29 May 2015
Change (% chg)

$1.19 (+1.99%)
Prev Close
$59.70
Open
$59.88
Day's High
$61.12
Day's Low
$59.47
Volume
20,015,567
Avg. Vol
11,456,848
52-wk High
$63.62
52-wk Low
$52.49

MRK

Chart for MRK

About

Merck & Co., Inc., is a health care company. The Company delivers health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products, which it markets directly and through its joint ventures. The Company’s operations are principally managed on a products basis and are... (more)

Overall

Beta: 0.32
Market Cap(Mil.): $172,027.80
Shares Outstanding(Mil.): 2,825.22
Dividend: 0.45
Yield (%): 2.96

Financials

  MRK Industry Sector
P/E (TTM): 15.80 37.18 39.28
EPS (TTM): 3.85 -- --
ROI: 13.04 16.31 15.64
ROE: 22.85 17.08 16.64
Search Stocks

Merck immunotherapy appears effective in head and neck cancer-study

- A Merck & Co drug that helps the immune system fight cancer was about twice as effective as the current standard therapy for patients with recurrent or advanced head and neck cancers, according to study data released on Friday.

29 May 2015

UPDATE 1-Merck immunotherapy appears effective in head and neck cancer-study

May 29 - A Merck & Co drug that helps the immune system fight cancer was about twice as effective as the current standard therapy for patients with recurrent or advanced head and neck cancers, according to study data released on Friday.

29 May 2015

New drugs from Bristol, Merck at forefront of cancer meeting

- New data to be released this weekend should help deepen the understanding of how broadly new drugs that unleash the body's immune system to fight cancer can be used.

28 May 2015

Merck offers EU concessions over $17 bln Sigma-Aldrich buy

BRUSSELS, May 27 - German drugmaker Merck has offered concessions in a bid to convince European Union antitrust regulators to clear its proposed $17 billion acquisition of U.S. peer Sigma-Aldrich Corp.

27 May 2015

DIARY-U.S. MEETINGS/WEEK AHEAD

Thomson Reuters May 26, 2015 - Corporate Meetings for US companies for Week ahead. S&P 500 Earnings - MONTH AHEAD Dividends Non S&P 500 - Weekly Federal Reserve events ConferenceCall/Webcast - Weekly Meetings - Weekly Xtra users can see more details on conference calls & webcasts by hovering your mouse over the RIC, right click, no click on Related Co Data, now click on Co Events. ** For

26 May 2015

DIARY-U.S. MEETINGS/WEEK AHEAD

Thomson Reuters May 25, 2015 - Corporate Meetings for US companies for Week ahead. S&P 500 Earnings - MONTH AHEAD Dividends Non S&P 500 - Weekly Federal Reserve events ConferenceCall/Webcast - Weekly Meetings - Weekly Xtra users can see more details on conference calls & webcasts by hovering your mouse over the RIC, right click, no click on Related Co Data, now click on Co Events. ** For

26 May 2015

U.S. bird flu causes egg shortage, emergency measures

CHICAGO/NEW YORK - As a virulent avian influenza outbreak continues to spread across the Midwestern United States, some egg-dependent companies are contemplating drastic steps - importing eggs from overseas or looking to egg alternatives. | Video

23 May 2015

DIARY-U.S. MEETINGS/WEEK AHEAD

Thomson Reuters May 22, 2015 - Corporate Meetings for US companies for Week ahead. S&P 500 Earnings - MONTH AHEAD Dividends Non S&P 500 - Weekly Federal Reserve events ConferenceCall/Webcast - Weekly Meetings - Weekly Xtra users can see more details on conference calls & webcasts by hovering your mouse over the RIC, right click, no click on Related Co Data, now click on Co Events. ** For

22 May 2015

Merck follows Bristol with EU green light for immune cancer drug

- European regulators have recommended approval of Merck & Co Inc's immune system-boosting cancer drug Keytruda, following a similar green light last month for Bristol-Myers Squibb Co's rival product Opdivo.

22 May 2015

Merck follows Bristol with EU green light for immune cancer drug

May 22 - European regulators have recommended approval of Merck & Co Inc's immune system-boosting cancer drug Keytruda, following a similar green light last month for Bristol-Myers Squibb Co's rival product Opdivo.

22 May 2015

Competitors

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider: Stock Traders Daily
$20.00
Provider: Stock Traders Daily
$20.00
Provider: Thomson Reuters Stock Report
$25.00
Provider: New Constructs, LLC
$25.00
Provider: Jefferson Research
$20.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Search Stocks